Dec 01, 2018
Novartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical program
Oct 02, 2018
Alcon introduces enhanced WaveLight® Refractive Suite to optimize the patient and surgeon LASIK experience
Aug 02, 2018
Novartis announces US renewables agreement to reduce greenhouse gas emissions
Jul 20, 2018
Alcon introduces NGENUITY® 3D Visualization System with DATAFUSION(TM) to simplify, customize vitreoretinal surgery
Jul 18, 2018
Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Jul 12, 2018
Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community
Jul 06, 2018
Sandoz Inc. and its affiliate, Novartis Pharmaceuticals Corporation, voluntarily recall select blister packages of products in the U.S. due to packaging requirements for child resistance
Jun 27, 2018
Novartis announces funding for patient advocacy initiatives to support and empower metastatic breast cancer community
Jun 19, 2018
Novartis receives FDA approval for inclusion of new evidence that Cosentyx® inhibits progression of joint structural damage in psoriatic arthritis
Jun 16, 2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Jun 15, 2018
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients' quality of life
Jun 03, 2018
Third Novartis Phase III trial shows Kisqali® combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer
Jun 02, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
May 30, 2018
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
May 17, 2018
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
May 11, 2018
Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis
May 01, 2018
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Apr 30, 2018
Novartis receives FDA approval of Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600-mutant melanoma
Apr 25, 2018
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
Apr 10, 2018
Novartis drug Afinitor DISPERZ® receives FDA approval to treat TSC-associated partial-onset seizures